(Q36313119)

13 August 2017

0 references

Pregabalin: a new neuromodulator with broad therapeutic indications (English)

1 reference

13 August 2017

main subject

therapeutic indication

1 reference

Bassel F Shneker

1

1 reference

13 August 2017

James W McAuley

series ordinal

2

1 reference

13 August 2017

language of work or name

English

0 references

publication date

15 November 2005

1 reference

Annals of Pharmacotherapy

13 August 2017

published in

1 reference

13 August 2017

volume

39

1 reference

13 August 2017

issue

12

1 reference

13 August 2017

page(s)

2029-2037

1 reference

Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C

13 August 2017

cites work

1 reference

Pregabalin pharmacology and its relevance to clinical practice

21 January 2018

1 reference

Comparison of resource utilization by patients treated with transdermal fentanyl and long-acting oral opioids for nonmalignant pain

21 January 2018

1 reference

Pharmacokinetics of pregabalin in subjects with various degrees of renal function

21 January 2018

1 reference

Clinical pharmacokinetics of newer antiepileptic drugs. Lamotrigine, vigabatrin, gabapentin and oxcarbazepine

21 January 2018

1 reference

Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII)

21 January 2018

1 reference

Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures

21 January 2018

1 reference

Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial

21 January 2018

1 reference

Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens

21 January 2018

1 reference

Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial.

21 January 2018

1 reference

Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial

21 January 2018

1 reference

Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial

21 January 2018

1 reference

Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial

21 January 2018

1 reference

The MOS 36-ltem Short-Form Health Survey (SF-36)

21 January 2018

1 reference

Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy

21 January 2018

1 reference

Practice parameter: treatment of postherpetic neuralgia: an evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures

21 January 2018

1 reference

Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy

21 January 2018

1 reference

Pregabalin as adjunctive therapy for partial seizures

21 January 2018

1 reference

Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey

21 January 2018

1 reference

Economic costs of anxiety disorders.

21 January 2018

1 reference

Pregabalin in generalized anxiety disorder: a placebo-controlled trial

21 January 2018

1 reference

Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing

21 January 2018

1 reference

Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam

21 January 2018

1 reference

REPLICATION OF FACTORS OF PSYCHOPATHOLOGY IN INTERVIEW, WARD BEHAVIOR AND SELF-REPORT RATINGS OF HOSPITALIZED DEPRESSIVES

21 January 2018

1 reference

The assessment of anxiety states by rating

21 January 2018

1 reference

Epidemiology, patterns of comorbidity, and associated disabilities of social phobia.

21 January 2018

1 reference

Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study

21 January 2018

1 reference

Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial

21 January 2018

1 reference

21 January 2018

1 reference

A rating scale for depression

21 January 2018

1 reference

Myoclonus in epilepsy patients with anticonvulsive add-on therapy with pregabalin.

21 January 2018

1 reference

Long-term Therapeutic Use of Benzodiazepines

21 January 2018

1 reference

Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy

21 January 2018

1 reference

Exposure-response analysis of pregabalin add-on treatment of patients with refractory partial seizures

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1G078

1 reference

13 August 2017

1 reference